Latest news with #Omnicell
Yahoo
a day ago
- Business
- Yahoo
Pharmacy Automation Strategic Research Report 2025-2030: Increasing Demand for Remote and Telepharmacy Services Drives Technology Adoption and Focus on Cost Reduction and Efficiency in Pharmacies
The global Pharmacy Automation market is projected to grow from USD 6.6 Billion in 2024 to USD 9.9 Billion by 2030, at a CAGR of 6.9%. This growth is driven by technological advancements and the increasing demand for efficient medication dispensing. The report provides an in-depth analysis of market trends, drivers, and forecasts, including key segments like Medication Dispensing Systems, which is expected to reach USD 3.3 Billion by 2030. Regional insights highlight significant growth in the U.S. and China. Key players include ARxIUM, Baxter, and Omnicell. Pharmacy Automation Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmacy Automation - Global Strategic Business Report" report has been added to global market for Pharmacy Automation was valued at US$6.6 Billion in 2024 and is projected to reach US$9.9 Billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Pharmacy Automation market. The growth in the pharmacy automation market is driven by several factors. Firstly, the increasing demand for efficient and error-free medication dispensing systems is propelling the adoption of automation technologies. Technological advancements in robotics, AI, and IoT are enhancing the capabilities of pharmacy automation systems, making them more reliable and efficient. The rising incidence of chronic diseases and an aging population are increasing the volume of medications dispensed, necessitating more efficient pharmacy operations. Additionally, the growing emphasis on reducing medication errors and improving patient safety is driving the demand for automated systems. The expansion of hospital infrastructure and the growth of retail pharmacies are also contributing to market growth. Furthermore, regulatory pressures for compliance with drug safety standards are encouraging the adoption of pharmacy automation solutions. These factors collectively support the robust growth and continuous innovation within the pharmacy automation Medication Management: The Emergence of Pharmacy AutomationPharmacy automation refers to the use of technology and machinery to handle and streamline various tasks in a pharmacy setting, such as medication dispensing, packaging, labeling, and inventory management. This automation significantly reduces the risk of human error, enhances operational efficiency, and allows pharmacists to focus more on patient care and consultation. In hospital and retail pharmacies, automated systems ensure the accurate dispensing of medications, which is critical for patient safety. Automated processes also improve the management of drug inventories, reducing waste and ensuring that medications are always in stock. Overall, pharmacy automation represents a transformative shift in the pharmaceutical industry, improving accuracy, efficiency, and patient Is Technology Transforming Pharmacy Operations?Technological advancements have profoundly impacted pharmacy operations, driving the adoption of sophisticated automation systems. Modern pharmacy automation solutions include robotic dispensing systems, automated medication storage and retrieval systems, and electronic prescription processing. Robotics and AI-driven systems can handle repetitive tasks with high precision, drastically reducing dispensing errors and freeing up pharmacists for more clinical duties. Integration of electronic health records (EHR) with pharmacy automation systems ensures seamless data flow, enhancing the accuracy of medication dispensing and patient safety. Additionally, advancements in software and analytics enable better tracking of medication usage patterns, aiding in inventory management and forecasting. These technologies collectively enhance the overall efficiency of pharmacy operations, contributing to improved healthcare Role Does Pharmacy Automation Play in Healthcare Compliance?Pharmacy automation plays a vital role in ensuring compliance with healthcare regulations and standards. Automated systems are designed to adhere to stringent guidelines for medication dispensing, labeling, and documentation, minimizing the risk of non-compliance. They provide accurate records of medication transactions, which are essential for audits and regulatory reporting. Automation also supports adherence to drug safety protocols, such as monitoring for potential drug interactions and ensuring proper dosing. Furthermore, automated systems facilitate compliance with privacy laws, such as HIPAA, by securing patient information and limiting access to authorized personnel only. By ensuring adherence to regulatory requirements, pharmacy automation enhances the overall safety and reliability of pharmaceutical Scope Key Insights: Market Growth: Understand the significant growth trajectory of the Medication Dispensing Systems segment, which is expected to reach US$3.3 Billion by 2030 with a CAGR of a 6.6%. The Packaging & Labeling Systems segment is also set to grow at 9.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.8 Billion in 2024, and China, forecasted to grow at an impressive 6.4% CAGR to reach $1.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as ARxIUM, Inc., Baxter International, Inc., Becton, Dickinson and Company, Capsa Healthcare, Cerner Corporation and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Segments: Medication Dispensing Systems Packaging & Labeling Systems Tabletop Counters Storage & Retrieval Systems Other Products Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 116 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.6 Billion Forecasted Market Value (USD) by 2030 $9.9 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Pharmacy Automation - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) Global Economic Update MARKET TRENDS & DRIVERS Increasing Demand for Efficient and Error-Free Medication Dispensing Spurs Growth Technological Advancements in Robotics Strengthen Business Case for Automation Rising Focus on Reducing Medication Errors Drives Adoption of Automated Systems Growing Need for Workflow Optimization in Pharmacies Expands Market Opportunity Integration of IoT in Pharmacy Systems Generates Demand for Smart Solutions Development of Compact and User-Friendly Automation Solutions Growth in Retail and Hospital Pharmacies Sustains Demand Expansion of Centralized Pharmacy Models Boosts Market Growth Demand for Remote and Telepharmacy Services Drives Technology Adoption Increasing Focus on Cost Reduction and Efficiency in Pharmacies Rising Awareness and Adoption of Automated Medication Management Systems FOCUS ON SELECT PLAYERS ARxIUM, Inc. Baxter International, Inc. Becton, Dickinson and Company Capsa Healthcare Cerner Corporation KUKA AG Omnicell, Inc. Parata Systems, LLC. RxSafe, LLC. ScriptPro LLC Talyst Tcgrx Pharmacy Workflow Solutions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmacy Automation Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
American Airlines, Omnicell, Integra LifeSciences, Enovis, and Warby Parker Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Travel and Vacation Providers company American Airlines (NASDAQ:AAL) jumped 5.1%. Is now the time to buy American Airlines? Access our full analysis report here, it's free. Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) jumped 5.5%. Is now the time to buy Omnicell? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) jumped 5.4%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 5.6%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Beauty and Cosmetics Retailer company Warby Parker (NYSE:WRBY) jumped 5.1%. Is now the time to buy Warby Parker? Access our full analysis report here, it's free. Enovis's shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 15 days ago when the stock gained 10.2% on the news that the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. Enovis is down 24.2% since the beginning of the year, and at $33.57 per share, it is trading 33.2% below its 52-week high of $50.27 from May 2024. Investors who bought $1,000 worth of Enovis's shares 5 years ago would now be looking at an investment worth $380.56. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Why Omnicell (OMCL) Stock Is Trading Up Today
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) jumped 5.9% in the afternoon session after the company reported impressive preliminary second quarter 2025 and full-year profit guidance due to reduced tariffs on imports in China. OMCL raised the lower end of its full-year EBITDA forecast and now expects it to fall within $120 million - $145 million (vs. previous guidance of $100 million - $145 million). EPS guidance was also raised to a range of $1.30 - $1.65 (vs. previous guidance of $1.00 - $1.65). Is now the time to buy Omnicell? Access our full analysis report here, it's free. Omnicell's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Omnicell is down 35% since the beginning of the year, and at $28.80 per share, it is trading 45.7% below its 52-week high of $53.05 from October 2024. Investors who bought $1,000 worth of Omnicell's shares 5 years ago would now be looking at an investment worth $438.76. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
Omnicell OMCL has announced new products aimed at streamlining workflows and improving inventory visibility and management in perioperative and clinic settings. The offerings are a new line of RFID products, MedTrack, and a web-enabled software product named MedVision. The latest development expands the company's connected platform, intended to automate medication management processes and deliver intelligent insights to drive clinical and operational outcomes across all settings of care. After the announcement yesterday, OMCL shares remained stable in the after-hours session. The ongoing staffing shortages in healthcare facilities and enterprise expansion lead to disconnected systems and processes, which often introduce opportunities for error and risk. By delivering scalable solutions that are designed to grow visibility, enhance intelligence and streamline workflows, Omnicell is helping close gaps in medication management across the care continuum. Accordingly, we expect the latest development to positively boost market sentiment toward OMCL stock. Omnicell has a market capitalization of $1.31 billion at present. Going by the Zacks Consensus Estimate, the company's 2025 revenues are expected to improve 1.4%. In the last reported quarter, it delivered an earnings surprise of 62.5%. The company believes that the path to the industry-defined vision of the Autonomous Pharmacy demands full visibility into medication use throughout the health system. The new MedTrack line of RFID products is designed to increase the accuracy and visibility of medications, streamline workflows and free time for clinicians to focus on higher-value work. Image Source: Zacks Investment Research The initial offering is MedTrack – OR, an RFID-enabled, single-deep drawer built to support operating room and anesthesia workflows and automatically track non-controlled medications without disrupting provider workflows. In the event of surgical emergencies, MedTrack OR is designed to provide instant access to essential medications while automatically updating Anesthesia WorkStation inventory counts once the user logs out. Meanwhile, Omnicell's MedVision software helps a health system's outpatient clinics restock medications directly from central pharmacies or Centralized Services Centers (CSCs). The solution is intended to provide real-time clinic medication inventory data accessible through intuitive dashboards. It is engineered to trigger automatic reordering from the central pharmacy or CSC when established par levels get low. The software also offers mobile device support for on-the-go inventory management in clinic storerooms and an optional integration with Epic medication administration record (MAR), which is built to automatically update inventory when a medication is administered from the electronic health record. Per a Mordor Intelligence report, the global Hospital Asset Tracking and Inventory Management Systems market is expected to reach $31.05 billion in 2025 and expand at a compound annual growth rate (CAGR) of 5.5% through 2030. The market continues to witness significant transformation driven by technological advancements and the need for operational efficiency. Concurrently, Omnicell announced the opening of its Austin, Texas Innovation Lab, which will serve as a hub focused on addressing challenges along the medication and supply journey. The facility will develop new technologies that are designed to solve evolving challenges faced by the healthcare industry. Over the past three months,Omnicell shares have declined 27.4% compared with the industry's fall of 9.5%. Omnicell currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, Inspira Medical Systems INSP and Cardinal Health CAH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Estimates for Hims & Hers Health's 2025 earnings per share have jumped 9.4% to 70 cents in the past 30 days. Shares of the company have surged 336.5% in the past year compared with the industry's 21% growth. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. Inspira shares have dipped 2% in the past year. Estimates for the company's 2025 earnings per share have increased 2.6% to $2.26 in the past 30 days. INSP's earnings beat estimates in each of the trailing four quarters, the average surprise being 356.9%. In the last reported quarter, it posted an earnings surprise of 143.5%. Estimates for Cardinal Health's fiscal 2025 earnings per share have increased 1.9% to $7.94 in the past 30 days. Shares of the company have jumped 50.4% in the past year against the industry's 3.5% fall. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. In the last reported quarter, it delivered an earnings surprise of 9.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Omnicell, Inc. (OMCL) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
14-05-2025
- Business
- Yahoo
Omnicell Announces New Products for Perioperative and Clinic Settings
RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics FORT WORTH, Texas, May 14, 2025--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical and operational outcomes across all settings of care. "As healthcare facilities face ongoing staffing shortages and enterprise expansion, we believe resulting disconnected systems and processes introduce opportunities for error and risk," said Nish Parekh, senior vice president and chief product officer at Omnicell. "Omnicell is focused on delivering scalable solutions that are designed to grow visibility, enhance intelligence, and streamline workflows, ultimately helping to close gaps in medication management across the care continuum." MedTrack RFID Line We believe the path to the industry-defined vision of the Autonomous Pharmacy demands full visibility to medication use throughout the health system. RFID tracking of medications is expected to provide enhanced visibility of tagged medications. When incorporated into existing pharmacy automation, it should drive more efficient workflows, and is anticipated to help reduce medication errors, stockouts, waste, and cost. Omnicell has announced the launch of a new line of RFID products, MedTrack, that are intended to increase accuracy and visibility of medications, make user workflows more efficient, and free time for clinicians to focus on higher value work. The initial offering is MedTrack – OR, an RFID-enabled, single-deep drawer that is built to support operating room and anesthesia workflows and is designed to automatically track non-controlled medications without disrupting provider workflows. This is intended to help enable providers to focus on patient care versus documentation and to enable a 'grab-and-go' medication dispensing workflow. In the event of surgical emergencies, MedTrack OR is designed to provide instant access to essential medications while automatically updating Anesthesia WorkStation inventory counts once the user logs out. Automating this layer of medication tracking is expected to help clinical teams enhance provider satisfaction and patient safety and help ensure inventory accuracy and reduce stockouts. MedVision Outpatient clinics are often areas where health systems lack insight and control of medication inventory. Many of these settings are driven by manual processes such as hand-written tabulation and fax/email ordering has the potential to introduce inconsistencies and may lead to stockouts and higher drug costs. MedVision is a web-enabled software product designed to deliver workflows and inventory management tools to help enable a health system's outpatient clinics to restock medications directly from central pharmacies or Centralized Services Centers (CSCs). The solution is intended to provide real-time clinic medication inventory data that is accessible through intuitive dashboards. It is engineered to trigger automatic reordering from the central pharmacy or CSC when established par levels get low. The software also offers mobile device support for on-the-go inventory management in clinic storerooms and an optional integration with Epic medication administration record (MAR) that is built to automatically update inventory when a medication is administered from the electronic health record. "MedVision helps us optimize medication procurement for our clinics," says Brandon McLain, Associate Vice President of Pharmacy Operations at Baptist Health. "The software allows our clinics to order medications in individual unit doses, something we were unable to do through our wholesalers, which helps us reduce costs and waste. The automatic reordering functionality also ensures our clinic nurses and medical assistants don't have to worry about the drug procurement side of the business, keeping them focused on patient care." Omnicell Innovation Lab Earlier today, Omnicell announced the opening of the Company's new Innovation Lab in Austin, Texas, a hub dedicated to addressing challenges across the medication and supply management journey. The Innovation Lab aims to be uniquely focused on defining and delivering opportunities that are intended to make healthcare operations more efficient and drive improved clinical and operational outcomes. We believe the opening of this new facility underscores Omnicell's ongoing commitment to delivering innovation that is outcome-driven and designed to ease the burden on frontline staff in support of safer, smarter care. To learn more about Omnicell's outcomes-centric solutions, visit About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy and nursing care through outcomes-centric solutions designed to deliver clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics and smart devices, intelligent software workflows, and data and analytics, all optimized by expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit From time to time, Omnicell may use the Company's investor relations website and other online social media channels, including its Twitter handle LinkedIn page and Facebook page to disclose material non-public information and comply with its disclosure obligations under Regulation Fair Disclosure ("Reg FD"). OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries. Forward-Looking Statements To the extent any statements contained in this press release deal with information that is not historical, these statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," "estimate," "seek," "predict," "project," and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell's control. Such statements include, but are not limited to, Omnicell's expectations regarding our planned new products, solutions, services, technologies and innovations and developing new or enhancing existing products, solutions, services, technologies and innovations, including our MedTrack RFID Line, MedTrack – OR, MedVision or the Innovation Lab, and the related objectives and expected benefits (and any implied financial impact), maximizing technology in an effort to enhance clinical and operational outcomes and statements about Omnicell's strategy, plans, objectives, promise and purpose, goals, opportunities, and growing the Company's portfolio. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell's ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iii) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (iv) risks related to Omnicell's investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (v) risks related to failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers, (vi) Omnicell's ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (vii) risks related to the incorporation of artificial intelligence technologies into our products, services and processes or our vendors offerings, (viii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (ix) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity related to the same, (x) any disruption in Omnicell's information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xi) Omnicell's ability to recruit and retain skilled and motivated personnel, (xii) Omnicell's ability to protect its intellectual property, (xiii) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xiv) Omnicell's dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, and (xv) other risks and uncertainties further described in the "Risk Factors" section of Omnicell's most recent Annual Report on Form 10-K, as well as in Omnicell's other reports filed with or furnished to the United States Securities and Exchange Commission ("SEC"), available at Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law. View source version on Contacts Betsy MartinelliDirector, Corporate Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
